PT  - JOURNAL ARTICLE
AU  - Kuznar, Wayne
ED  - Sinn, Marianne
TI  - SOR as Adjuvant Therapy after Resection for Pancreatic Cancer Does Not Improve DFS
DP  - 2014 Dec 01
TA  - MD Conference Express
PG  - 21--21
VI  - 14
IP  - 36
4099  - http://mdc.sagepub.com/content/14/36/21.short
4100  - http://mdc.sagepub.com/content/14/36/21.full
AB  - Even after successful surgery intended as curative, up to 90% of patients with pancreatic cancer suffer a relapse. Adding sorafenib to gemcitabine as adjuvant therapy for patients after R1 resection for pancreatic cancer does not improve disease-free survival or overall survival compared with GEM alone. This article presents results from the phase 2b CONKO-006 study.